Atrophic vaginitis is a condition that commonly occurs in postmenopausal women characterized by thinning, drying, and inflammation of the vaginal walls due to decrease in estrogen levels. Products used in the treatment of atrophic vaginitis include creams, tablets, rings, and gels that help lubricate and moisturize the vaginal lining. With rapidly aging female population and rising number of women opting for hormone replacement therapy, the use of such atrophic vaginitis treatment products is increasing. The global Atrophic Vaginitis Treatment Market is estimated to be valued at US$ 658.33 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends driving the growth of the atrophic vaginitis treatment market is increasing prevalence of postmenopausal symptoms among women. With rising age, majority of women experience vaginal dryness, itching, irritation or pain during sexual intercourse due to decreased estrogen levels postmenopause. This makes them more prone to atrophic vaginitis. As per estimates, around 50-60% of postmenopausal women suffer from atrophic vaginitis worldwide. Growing health awareness about management of postmenopausal symptoms and availability of effective treatment options is encouraging more women to seek medical help. This is anticipated to fuel demand for atrophic vaginitis drugs and devices over the forecast period.

Segment Analysis

The global atrophic vaginitis treatment market is segmented on the basis of treatment type and distribution channel. Based on treatment type, the market is categorized into local estrogen therapy, systemic estrogen hormone therapy, non-hormonal therapy and others. The local estrogen therapy segment holds the largest market share owing to its effectiveness and fewest side effects. The segment includes vaginal estrogen products such as creams, tablets, and rings.

Key Takeaways

The global Atrophic Vaginitis Treatment market is expected to witness high growth. Regional analysis related content comprises

The North America region dominates the global atrophic vaginitis treatment market and is expected to continue its dominance during the forecast period. This is attributed to the developed healthcare infrastructure and rising prevalence of menopause in countries like the US and Canada. Additionally, presence of key players and availability of advanced treatment options in the region are supplementing market growth.

Key players

Key players operating in the atrophic vaginitis treatment market are Pfizer Inc., TherapeuticsMD Inc., Allergan plc (AbbVie Inc.), Duchesnay USA, Novo Nordisk A/S, Merck & Co., Inc., Endoceutics Inc., Bausch Health Companies Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd.

Pfizer Inc. offers vagifem tablets and uses it as an estrogen replacement therapy for treating vaginal dryness during menopause. TherapeuticsMD Inc. provides Imvexxy which is estradiol vaginal inserts for treating moderate-to-severe dyspareunia.
Get More Insights Here

https://healthcarelatesteditionnews.blogspot.com/2023/12/the-global-atrophic-vaginitis-treatment.html